A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 When Administered Concomitantly With Methotrexate

The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.

Inclusion Criteria:

• Adult patients 18 to 75 years of age with active RA
• Must have been taking MTX for at least 6 months
• No concurrent DMARD treatment (other than a stable dose of MTX)

Exclusion Criteria:

• Planned major surgery (e.g., joint replacement) within the duration of the treatment period of the study
• Treated with intra-articular injections of corticosteroids within 28 days prior to Day 1